Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.
作者信息
Perel Galina, Bliss Joshua, Thomas Christan M
出版信息
P T. 2016 May;41(5):303-7.
Abstract
摘要
相似文献
1
Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.
P T. 2016 May;41(5):303-7.
2
Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
J Oncol Pharm Pract. 2013 Dec;19(4):348-54. doi: 10.1177/1078155212470388. Epub 2013 Jan 4.
3
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.
Blood Lymphat Cancer. 2017 Jul 19;7:53-60. doi: 10.2147/BLCTT.S82444. eCollection 2017.
4
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.
Ther Adv Hematol. 2016 Dec;7(6):330-344. doi: 10.1177/2040620716667275. Epub 2016 Sep 13.
5
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1.
6
Carfilzomib boosted combination therapy for relapsed multiple myeloma.
Onco Targets Ther. 2017 Feb 15;10:895-907. doi: 10.2147/OTT.S102756. eCollection 2017.
7
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.
8
Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Ann Pharmacother. 2013 Jan;47(1):56-62. doi: 10.1345/aph.1R561. Epub 2013 Jan 8.
9
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
10
Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Future Oncol. 2015;11(15):2121-36. doi: 10.2217/fon.15.123. Epub 2015 Jun 30.
引用本文的文献
1
Clinical use and toxicities of bortezomib in pediatric patients: a systematic review.
Front Pharmacol. 2025 Aug 6;16:1661493. doi: 10.3389/fphar.2025.1661493. eCollection 2025.
2
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study.
Pharmaceuticals (Basel). 2025 Apr 19;18(4):595. doi: 10.3390/ph18040595.
3
Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients.
Curr Issues Mol Biol. 2025 Jan 6;47(1):32. doi: 10.3390/cimb47010032.
4
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models.
Sci Rep. 2024 Mar 1;14(1):5135. doi: 10.1038/s41598-024-55143-0.
5
Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action.
Cancers (Basel). 2023 Dec 23;16(1):84. doi: 10.3390/cancers16010084.
6
Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel.
EJHaem. 2022 Nov 6;4(1):174-183. doi: 10.1002/jha2.595. eCollection 2023 Feb.
7
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Biomedicines. 2022 Sep 8;10(9):2233. doi: 10.3390/biomedicines10092233.
8
Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect.
BMJ Case Rep. 2022 Jul 4;15(7):e251173. doi: 10.1136/bcr-2022-251173.
9
The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF-κB signal transduction.
Cancer Biol Ther. 2021 Dec 2;22(10-12):479-492. doi: 10.1080/15384047.2021.1978785. Epub 2021 Sep 29.
10
Small Molecule NF-κB Pathway Inhibitors in Clinic.
Int J Mol Sci. 2020 Jul 21;21(14):5164. doi: 10.3390/ijms21145164.
本文引用的文献
1
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
2
Carfilzomib.
Blood. 2013 Feb 7;121(6):893-7. doi: 10.1182/blood-2012-10-459883.
3
Molecular pathogenesis of multiple myeloma and its premalignant precursor.
J Clin Invest. 2012 Oct;122(10):3456-63. doi: 10.1172/JCI61188. Epub 2012 Oct 1.
4
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25.
5
Quality of Life assessment through the EORTC questionnaires of colorectal cancer patients in advanced disease stages.
Clin Transl Oncol. 2006 Sep;8(9):664-71. doi: 10.1007/s12094-006-0036-6.
6
Structure and functions of the 20S and 26S proteasomes.
Annu Rev Biochem. 1996;65:801-47. doi: 10.1146/annurev.bi.65.070196.004101.
Zotero 插件